# POLD1

Source: https://onco.cc/targets/pold1/  
OnCo record `pold1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

POLD1 (DNA polymerase delta catalytic subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Lung cancer, Breast cancer and 5 more.

## Summary

As the catalytic component of the trimeric (Pol-delta3 complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 complex), plays a crucial role in high fidelity genome replication, including in lagging strand synthesis, and repair. Exhibits both DNA polymerase and 3'- to 5'-exonuclease activities. Requires the presence of accessory proteins POLD2, POLD3 and POLD4 for full activity.

CIViC holds 7 clinical evidence items and 0 assertions across 4 variants, naming Pembrolizumab, ATR Inhibitor and Chk1 Inhibitor. Open Targets scores its association with cancer at 0.88 (direct and indirect evidence; datatypes genetic literature 0.83, clinical 0.99, literature 0.97, genetic association 0.72, somatic mutation 0.86). IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Oesophageal Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: DNA polymerase delta 1, catalytic subunit; DNA polymerase delta catalytic subunit; CDC2
- Tags: cancer-genes-wave
- Symbol: POLD1
- Class: tumor-suppressor
- Biology: As the catalytic component of the trimeric (Pol-delta3 complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 complex), plays a crucial role in high fidelity genome replication, including in lagging strand synthesis, and repair. Exhibits both DNA polymerase and 3'- to 5'-exonuclease activities. Requires the presence of accessory proteins POLD2, POLD3 and POLD4 for full activity. Depending upon the absence (Pol-delta3) or the presence of POLD4 (Pol-delta4), displays differences in catalytic activity. Most notably, expresses higher proofreading activity in the context of Pol-delta3 compared with that of Pol-delta4. Although both Pol-delta3 and Pol-delta4 process Okazaki fragments in vitro, Pol-delta3 may be better suited to fulfill this task, exhibiting near-absence of strand displacement activity compared to Pol-delta4 and stalling on encounter with the 5'-blocking oligonucleotides. Location: Nucleus (UniProt). Locus 19q13.33 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.76 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease; Lung cancer: Open Targets association 0.73 with lung cancer (MONDO_0008903); Breast cancer: Open Targets association 0.73 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA); Leukaemia: Open Targets association 0.71 with leukaemia (MONDO_0005059); Non-Hodgkin lymphoma: Open Targets association 0.71 with non-Hodgkin lymphoma (MONDO_0018908); Ovarian cancer: Open Targets association 0.69 with ovarian cancer (MONDO_0008170)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 7 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9175: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9175
- UniProt P28340: https://www.uniprot.org/uniprotkb/P28340/entry
- NCBI Gene 5424: https://www.ncbi.nlm.nih.gov/gene/5424
- Ensembl ENSG00000062822: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000062822

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/pold1.json